Viva Biotech’s mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model.
Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers’ needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model.
As of June 30, 2020, Viva Biotech had provided drug discovery services to over 495 biotechnology and pharmaceutical customers worldwide, worked on over 1,300 independent drug targets, delivered over 17,000 protein complex structures and invested/ incubated a total of 56 early stage biotech start-ups.